Healio News

First patient dosed in global phase 3 trial of Rinvoq for hidradenitis suppurativa

Researchers have dosed the first patient in Step-Up HS, a phase 3 study evaluating Rinvoq for moderate to severe hidradenitis suppurativa in adults and adolescents, AbbVie announced in a press release.“Hidradenitis suppurativa is a chronic, inflammatory disease that often leads to irreversible skin damage and extreme pain for patients,” Roopal Thakkar, MD, senior vice president of development a

nd regulatory affairs and chief medical officer of AbbVie, said in the release. "Leveraging our proven expertise in immunology and experience in HS, we continue to drive innovation and

1 year 8 months ago

PAHO/WHO | Pan American Health Organization

Questions and answers on avian influenza A(H5N1)

Questions and answers on avian influenza A(H5N1)

Oscar Reyes

26 Jul 2023

Questions and answers on avian influenza A(H5N1)

Oscar Reyes

26 Jul 2023

1 year 8 months ago

Health

Stay hydrated in the summer heat

AS TEMPERATURES continue to climb for the summer, it is essential to stay hydrated. Hydration is always important, but especially in hot and humid weather, as we tend to lose a lot of our body fluids through sweat. The reason dehydration becomes a...

AS TEMPERATURES continue to climb for the summer, it is essential to stay hydrated. Hydration is always important, but especially in hot and humid weather, as we tend to lose a lot of our body fluids through sweat. The reason dehydration becomes a...

1 year 9 months ago

Health

Dance your way to better health

EXERCISE IS good for your body and your brain! Sticking to a regular workout plan can be tough, but including activity in your routine does not have to be boring. Scientists have found that the areas of the brain that control memory and skills such...

EXERCISE IS good for your body and your brain! Sticking to a regular workout plan can be tough, but including activity in your routine does not have to be boring. Scientists have found that the areas of the brain that control memory and skills such...

1 year 9 months ago

Health | NOW Grenada

Hillsborough Smart Health Centre equipped with autoclave

The equipment is highly appreciated and another example of the Diaspora continuing to play a major role in the development of the healthcare sector in the tri-island state

1 year 9 months ago

Health, PRESS RELEASE, autoclave, dannette blair-st bernard, gauze, hillsborough smart health centre, janelle harford, kwame abraham, lydia andrew, tevin andrews

Medical News, Health News Latest, Medical News Today - Medical Dialogues |

Why patients with gum disease are less likely to respond to RA treatment?

USA: A recent study suggests that breaches in damaged gums allow bacteria in the mouth to seep into the bloodstream, activating an immune response that ultimately pivots to target the body’s own proteins and causes arthritis flare-ups.

It’s a well-documented medical mystery: Patients with gum disease are less likely to respond to rheumatoid arthritis treatments. But the new research published in Science Translational Medicine has explained this link between gum disease and an otherwise disparate condition.

The study revealed a plausible mechanism to explain why rheumatoid arthritis patients with periodontal disease do not respond well to treatment-something very hard to capture without long-term monitoring.

“If oral bacteria are getting in and repeatedly triggering immune responses relevant to rheumatoid arthritis, that could make it harder to treat,” says Dana Orange, a professor of clinical investigation in the laboratory of Robert B. Darnell at Rockefeller University. “When doctors encounter arthritis patients who do not respond to treatment, it would be worth ensuring they aren’t missing an underlying gum disease, which is quite treatable.”

The Darnell lab had been following a small group of arthritis patients over the course of several years, collecting weekly blood samples and looking for changes in gene expression to help explain why painful flare-ups occurred when they noticed a surprising trend. Two of their patients, who had moderate to severe periodontal disease, had repeated episodes of oral bacteria in their bloodstreams, even when they didn’t have dental work.

Orange knew that rheumatoid arthritis patients generally have autoantibodies in their bloodstream (rheumatoid arthritis is an auto-immune disease, wherein antibodies attack the body’s own proteins and peptides). In many cases, autoantibodies take specific aim at proteins bearing the signs of citrullination, a process by which one amino acid in the protein is converted into a different one.

Upon further examination, the team discovered that the oral bacteria they detected in the blood are also citrullinated in the mouth, much like the proteins targeted by autoantibodies in arthritis. They then demonstrated that the same autoantibodies that take potshots at the body’s citrullinated proteins activate in response to citrullinated bacteria.

The results may explain why arthritis treatments do not work as well in patients with gum disease. If the gums continuously release immune triggers into the bloodstream, treating arthritis without first solving the periodontal problem is like trying to haul water out of a ship without first plugging up its leaks.

“Gum disease is quite curable; rheumatoid arthritis can be much more difficult to treat,” Orange says. “Our results indicate that periodontal disease leads to leaky gums that allow oral bacteria to enter the blood repeatedly. This level of oral bacteria in the blood doesn’t cause obvious symptoms, so the patients were unaware of this. Still, they trigger inflammatory and auto-antibody responses highly relevant to rheumatoid arthritis.”

These findings also demonstrate long-term research's importance in understanding chronic diseases better. The present study would not have been possible without a unique initiative, pioneered by Orange and Darnell several years ago, that empowers arthritis patients to collect their own blood samples at home with a finger-prick kit and mail weekly samples to Rockefeller. The lab has several years of data to help track what happens in the blood right before an arthritis flare.

“Without having weekly blood samples for at least a year, we wouldn’t have been able to find out what was happening before the patients had symptoms of their flares,” Orange says. “Our study revealed a plausible mechanism to explain why rheumatoid arthritis patients with periodontal disease do not respond well to treatment-something, very hard to capture without long-term monitoring.”

Reference:

R. Camille Brewer et al. ,Oral mucosal breaks trigger anti-citrullinated bacterial and human protein antibody responses in rheumatoid arthritis.Sci. Transl. Med.15, eabq8476(2023).DOI:10.1126/scitranslmed.abq8476.

1 year 9 months ago

Dentistry News and Guidelines,Medicine,Orthopaedics,Medicine News,Orthopaedics News,Dentistry News

Medical News, Health News Latest, Medical News Today - Medical Dialogues |

Mepolizumab Shows Promising Treatment of Severe Eosinophilic Asthma

In a recent multicenter study, Giulia Scioscia and peers found that in patients with severe eosinophilic asthma switching from mepolizumab to benralizumab can lead to improved treatment outcomes. The findings were published in Journal of Clinical Medicine.

Mepolizumab and benralizumab are monoclonal antibodies targeted against anti-IL-5 and anti-IL5R, respectively, and are commonly used in the treatment of severe eosinophilic asthma. These medications have been shown to reduce exacerbation rates and maintain oral corticosteroid requirements in patients with this condition.

The study included twenty-five patients with severe eosinophilic asthma who had been receiving mepolizumab for at least 12 months but showed a partial or total lack of clinical remission. The patients were switched to benralizumab, and their responses were assessed over a six-month period.

The results of the study revealed significant improvements in asthma control after the switch to benralizumab. At six months of treatment, patients exhibited significantly higher scores on the Asthma Control Test (ACT) compared to their scores while on mepolizumab. Furthermore, the number of daily short-acting beta-agonist (SABA) inhalations decreased significantly after six and twelve months of treatment with benralizumab compared to mepolizumab. Additionally, the intake of oral corticosteroids (OCS) was significantly reduced in patients receiving benralizumab.

Importantly, the study also identified a subgroup of patients with severe eosinophilic asthma and nasal polyposis who experienced marked improvements in asthma control, suppressed blood eosinophil levels, and a reduction in exacerbations following treatment with benralizumab.

These findings suggest that patients who initially showed a partial response to mepolizumab may benefit from switching to benralizumab. The study highlights the complexity of treating severe eosinophilic asthma and underscores the importance of personalized therapeutic choices based on individual patient factors. While this research provides valuable insights, further studies are warranted to validate these findings in larger patient populations and to explore the long-term effects of switching between these biologic medications. 

Source:

Scioscia, G., Tondo, P., Nolasco, S., Pelaia, C., Carpagnano, G. E., Caiaffa, M. F., Valenti, G., Maglio, A., Papia, F., Triggiani, M., Vatrella, A., Foschino Barbaro, M. P., & Crimi, C. (2023). Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience. In Journal of Clinical Medicine (Vol. 12, Issue 13, p. 4362). MDPI AG. https://doi.org/10.3390/jcm12134362

1 year 9 months ago

Medicine,Pulmonology,Medicine News,Pulmonology News,Top Medical News,Latest Medical News

Medical News, Health News Latest, Medical News Today - Medical Dialogues |

Poliprotect may improve heartburn symptoms among patients with normal upper GI endoscopy

A recent study published in The American Journal of Gastroenterology by Enrico Stefano Corazziari and team of researchers has demonstrated that Poliprotect, a mucosal protective agent, is noninferior to omeprazole in relieving heartburn and epigastric pain or burning in patients with normal upper gastrointestinal (GI) endoscopy findings.

This finding is significant as alternative treatment options are needed for patients who do not respond well to proton-pump inhibitors (PPIs) or who are unable to take PPIs due to factors such as pregnancy or infancy.

The randomized controlled trial involved 275 outpatients with endoscopy-negative findings who were randomly assigned to receive a 4-week treatment of either omeprazole (20 mg once daily) or Poliprotect (administered five times a day for the initial two weeks and on-demand thereafter). Following this, there was an open-label 4-week treatment period during which all participants received Poliprotect on-demand. The efficacy and safety of both treatments were assessed, along with changes in gut microbiota.

● Results showed that the 2-week treatment with Poliprotect was noninferior to omeprazole in terms of symptom relief.

● The between-group difference in the change in visual analog scale symptom score was -5.4 (95% confidence interval: -9.9 to -0.1) in the intention-to-treat population and -6.2 (95% confidence interval: -10.8 to -1.6) in the per-protocol population.

● Poliprotect's benefit remained consistent even when shifted to on-demand intake, and no significant changes were observed in the gut microbiota.

● Omeprazole initially provided symptom relief, it was associated with higher usage of rescue medicine sachets compared to Poliprotect.

● Omeprazole use was linked to an increased abundance of oral cavity genera in the intestinal microbiota.

● No relevant adverse events were reported in either treatment arm.

The findings suggest that Poliprotect is a viable alternative to standard-dose omeprazole for patients experiencing heartburn and epigastric burning without erosive esophagitis and gastroduodenal lesions. Furthermore, Poliprotect treatment did not adversely affect gut microbiota, which is an important consideration in maintaining a healthy balance of intestinal flora.

These promising results highlight the potential of Poliprotect as an effective and safe mucosal protective agent for the relief of heartburn and epigastric pain. Further research and larger-scale studies are warranted to confirm these findings and explore the long-term efficacy and safety of Poliprotect in a broader population.

Reference:

Corazziari, E. S., Gasbarrini, A., D’Alba, L., D’Ovidio, V., Riggio, O., Passaretti, S., Annibale, B., Cicala, M., Repici, A., Bassotti, G., Ciacci, C., Di Sabatino, A., Neri, M., Bragazzi, M. C., Ribichini, E., Radocchia, G., Iovino, P., Marazzato, M., Schippa, S., & Badiali, D. (2023). Poliprotect vs omeprazole in the relief of heartburn, epigastric pain, and burning in patients without erosive esophagitis and gastroduodenal lesions: A randomized, controlled trial. The American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000002360

1 year 9 months ago

Gastroenterology,Gastroenterology News,Top Medical News

PAHO/WHO | Pan American Health Organization

PAHO and Inter-American Development Bank celebrate 5-year collaboration on digital health in the Americas

PAHO and Inter-American Development Bank celebrate 5-year collaboration on digital health in the Americas

Cristina Mitchell

25 Jul 2023

PAHO and Inter-American Development Bank celebrate 5-year collaboration on digital health in the Americas

Cristina Mitchell

25 Jul 2023

1 year 9 months ago

Healio News

VIDEO: COVID adds difficulty in interpreting results of randomized trials

In this video, Jakub Svoboda, MD, discusses the results of the phase 3 Alliance study, pertaining to chronic lymphocytic leukemia, presented at ASCO Annual Meeting.Svoboda, an associate professor of medicine at Hospital of the University of Pennsylvania, highlighted the study, which examined the impact of adding venetoclax (Venclexta; Genentech, AbbVie) to the standard combination therapy of ib

rutinib (Imbruvica; Pharmacyclics, Janssen) and obinutuzumab (Gazyva, Genentech) in older patients with CLL. Svoboda also pondered the effect COVID-19 had on health outcomes in randomized trials.“You

1 year 9 months ago

Medical News, Health News Latest, Medical News Today - Medical Dialogues |

MCC NEET PG, MDS Counselling 2023: Check Out Registration, Counselling Process, Eligibility Criteria Details Here

Delhi: The Medical Counselling Committee (MCC) has released the information bulletin for MD, MS, MDS, and DNB admissions for the academic year 2023-24.

All the concerned candidates are advised to take note of all the below-mentioned details including registration and counselling process, quota-wise eligibility criteria before applying with the MCC for PG medical and dental admissions this year.

PG Counselling conducted by MCC can only be submitted online through the Medical Counselling Committee website www.mcc.nic.in. Registration submitted through any other mode shall be summarily rejected. Candidates are further advised to fill out the application form on their own/self on the MCC website and not through any agent or third party.

Only Qualified/ eligible candidates must register on the MCC website i.e., www.mcc.nic.in to participate in the counseling process for allotment of seats. MCC does not allot any seat either on a nomination basis/ manually or in offline mode.

A candidate can submit the NEET-PG Counselling application/registration form only once. Any candidate found to have submitted more than one application/registration form for NEET-PG Counselling shall be debarred from the NEET-PG Counselling allotment process, his/her candidature shall be canceled and further action as deemed appropriate by the MCC of DGHS, MoHFW shall be taken.

The Security Deposit will be forfeited if a candidate who has been allotted a seat in the Second Round or subsequent rounds does not join the respective institution or surrender the seat due to any unforeseen reason. Also, the Security Deposit will be forfeited if the admission gets canceled due to any reason.

Registering for NEET-PG Counselling does not confer any automatic rights to secure a Post Graduate seat. The selection and admission to Post Graduate seats in any medical Institution recognized for running Post Graduate courses as per Indian Medical Council Act, 1956 is subject to fulfilling the merit, admission criteria, eligibility, and such criteria as may be prescribed by the respective universities, medical institutions, Medical Council of India, State/Central Government.

Candidates should ensure that all the information filled in during the online submission of the application/registration form is correct and factual. Information provided by the candidates in the online application/registration form shall be treated as correct and self-certified and MCC shall not entertain, under any circumstances, any request for change in the information provided by the candidates.

MCC does not change/ edit /modify/alter any information entered by the candidates at the time of online submission of application/registration for counseling under any circumstances. The information regarding Stipend /fee structure/ course duration/bond amount/rendering of service in rural/tribal areas/other conditions etc. has been provided by Medical/Dental Colleges on the MCC website.

Candidates must confirm their eligibility/domicile status before registering on the MCC website for Institutional Quota seats of Central Universities/Institutes/ Deemed Universities before opting for their seats. They must confirm the fee structure/ any other additional fee from the colleges especially Deemed Universities before filling up choices for the same.

Candidates must use the Mobile number/email id used by them during registration on the NBE website for the MCC counseling registration process. The said Email ID and Mobile number shall only be used/pre-populated during the counseling registration process. OTPs etc. will only be sent to the registered mobile number and email ids.

The refund process will commence only after the completion of all the rounds of Counselling. MCC will not entertain any query either through email or phone call with regard to a refund before the completion of all the rounds of counseling.

Candidates note that they will be shown only the Clear-cut Vacancies in Round 1. Also, the vacancy position of the seats will be shown in three categories.

Round 2, which are as follows -

1. Clear-cut vacancies- The seats which have not been allotted in Round 1

2. Virtual Vacancies- Any Candidate who has been allotted a seat in Round 1 and has opted for up-gradation in Round 2, the allotted seats of Round 1 will be shown as virtual vacancies in Round 2 and Candidates can fill the said seat during the choice filling in Round 2. However, such seats will be allotted in Round 2 if the allottee of Round 1 vacates/upgrades in Round 2

Each round of counselling is a separate round and the rules of each round are different. Once any round commences, the rules of that round will apply to all the candidates even if they were allotted/admitted in the previous round(s) of counseling. The rules of round 1 will only apply to the rules of round 1. Once Round 2 commences the rules of Round 2 shall apply and the rules of Round 1 will not apply. Similarly, the rules of the third round will apply only in the third round and the rules of the Stray Vacancy round will apply only in the stray vacancy round.

Candidates should make sure that while taking admission/resignation in the allotted college their admission/resignation is generated through online mode i.e. through the intra-MCC portal by the college authorities. Any other letter of admission/resignation will not be accepted.

Candidates who have an international number must provide an alternative Indian number at the time of registration for the counseling process.

Disability certificate- the Candidates must obtain their online disability certificate from the designated disability board in an online mode generated by the disability Centre as per the NMC norms before the choice filling commences. Only Candidates who have made their disability certificate through online mode from the designated centers will be eligible to fill in the PwD choices. MCC of DGHS does not issue/authenticate/verify and has no role in the generation of online Disability certificates.

INSTRUCTIONS FOR FILLING ONLINE APPLICATION FORM –

Candidates are informed that the e-mail ID and Mobile Number provided in the Online Application Form of NBE will be used for registration on the MCC portal for Counselling. The said fields will be pre-populated in the Application/Registration form of Counselling. All the information/ communication will be sent by MCC of DGHS, MoHFW through email on the registered e-mail address or SMS on the registered Mobile Number only.

Any complaint with regard: to the change of registered mobile number or email address shall not be entertained by the MCC of DGHS, MoHFW.

Candidates are advised to use Laptop or Computer along with the latest registered version of Chrome/Internet Explorer/Firefox/Windows/IOS and a good internet connection during the Registration and Choice-Filling process to avoid any technical complications.

Please note that the registration facilities will be available at the beginning of the first round, second round, third round, and stray vacancy on notified dates. Under no circumstances any request (for any reason) for registration, shall be entertained after the closing of registration.

The seat allotted candidates will have to upload essential certificates after the declaration of results as per the scheduled date. It is mandatory for candidates to carry their original documents during physical reporting to the college/institute for confirmation /joining of the seat.

Candidates are informed that the e-mail ID and Mobile Number provided in the Online Application Form of NBE will be used for registration on the MCC portal for Counselling. The said fields will be pre-populated in the Application/Registration form of Counselling. All the information/ communication will be sent by MCC of DGHS, MoHFW through email on the registered e-mail address or SMS on the registered Mobile Number only.

Any complaint with regard: to the change of registered mobile number or email address shall not be entertained by the MCC of DGHS, MoHFW.

Candidates are advised to use Laptop or Computer along with the latest registered version of Chrome/Internet Explorer/Firefox/Windows/IOS and a good internet connection during the Registration and Choice-Filling process to avoid any technical complications.

Please note that the registration facility will be available at the beginning of the first round, second round, third round, and stray vacancy on notified dates. Under no circumstances any request (for any reason) for registration, shall be entertained after the closing of registration.

The seat allotted candidates will have to upload essential certificates after the declaration of results as per the scheduled date. It is mandatory for candidates to carry their original documents during physical reporting to the college/institute for confirmation /joining of the seat.

The candidates need to refer to a counseling scheme for each below round -

1. ROUND-1 (Start & End)

2. ROUND-2 (Start& End)

3. ROUND-3 (Start& End)

4. STRAY VACANCY ROUND

The details related to each round are mentioned in the notice below.

COUNSELLING STAGES –

1. Round 1- AIQ, Deemed, Central Universities & DNB

2. AIQ Round 2-AIQ, Deemed, Central Universities & DNB

3. Third Round- AIQ, Deemed, Central Universities & DNB

4. Stray Vacancy- AIQ, Deemed, Central Universities & DNB. For AIQ and Central Universities/Institutes /Deemed Universities - MCC will conduct the counseling

Result –

The counseling for NEET-PG is conducted by MCC based on the result of qualified candidates sent by NBE. The whole counseling process is completely automated without any manual intervention. MCC uploads the provisional result initially in every round for verification of the candidates/colleges/institute based on their choices, merit, and eligibility.

Once the Candidates are allotted a seat based on their merit, choice & eligibility, in any of the Rounds of counseling conducted by MCC, the Candidates will be required to download their ‘allotment letter’ from the MCC website (www.mcc.nic.in). If the Candidate is satisfied with his/her allotment he/she may approach the allotted college/institute for completing the admission formalities within the reporting time schedule.

Admission –

If the Candidate is satisfied with his/her allotment he/she may approach the allotted college/institute for completing the admission formalities.

Original documents required at the time of joining in allotted Medical/Dental College are as mentioned below -

Allotment Letter issued by MCC (Essential document).

Admit Card issued by NBE.

Result/Rank Letter issued by NBE.

Mark Sheets of MBBS/BDS 1st, 2nd & 3rd Professional Examinations.

MBBS/ BDS Degree Certificate/ Provisional Certificate. (Essential document).

Internship Completion Certificate/Certificate from the Head of Institution or College that the candidate shall complete the Internship by 31st March, of the year of admission/ or if required the date as decided by the Competent Authority.

Permanent / Provisional Registration Certificate issued by MCI/NMC or DCI/State Medical or Dental Council. A provisional Registration Certificate is acceptable only in cases where the candidate is undergoing an internship and likely to complete the same on or before 31st March of the year of admission. (Essential document)

High School/Higher Secondary Certificate/Birth Certificate as proof of date of birth. (Essential document)

Candidates allotted seat must carry one of the identification proofs (ID Proof) to the allotted college at the time of admission (as mentioned in the information Bulletin published by the National Board of Examinations (NBE) for NEET i.e. PAN Card, Driving License, Voter ID, Passport or Aadhaar Card).

The Candidate should also bring the following certificates, if applicable:

SC/ST Certificate issued by the competent authority (in the format specified in the Information Bulletin) should be in English or Hindi. Sub-caste should be clearly mentioned in the certificate. The translated certificate must be certified by a Gazetted Officer. (Essential document)

EWS Certificate as per the Central Govt. Norms (in the format as specified in the Information Bulletin) should be in English or Hindi language. The translated certificate must be certified by a Gazetted Officer. (Essential document)

OBC certificate issued by the competent authority. The sub-caste should tally with the Central List of OBC. The OBC candidates should not belong to Creamy Layer. The OBC certificate must be in the format mentioned in the prospectus. The translated certificate must be certified by a Gazetted Officer. (Essential document).

Disability Certificate issued from a duly constituted and authorized Medical Board for 21 Benchmark Disabilities as per the Rights of Persons with Disability Act,2016, and NMC Norms. No other certificate, issued by any other Authorities/ Hospital will be entertained. The format of the Certificate of Disability is annexed (1,2) in the Information Bulletin. (Essential document)

Details related to quotas - 

ALL INDIA QUOTA –

There will be four rounds of AIQ counseling i.e. Round 1, Round 2, A I Q third Round, and AIQ Stray Vacancy Round (SLA(C) No. 10487 of 2021 before the Hon’ble Supreme Court of India). All candidates who have qualified for All India Quota seats on the basis of their rank in NEET PG conducted by the National Board of Examination (NBE) will be eligible for participation in the counseling process. Eligible candidates may download the Rank letter/ Result from the NBE website. The cut-off rank of eligible candidates will also be available on the MCC website (www.mcc.nic.in).

Open seats-domicile free includes -

1. 50% All India Quota seats

2. 50%Seats of BHU

3. 50%Seats of AMU

4. 50% All India Quota seats of DU/Central Institutes (VMMC & SJH, ABVIMS & RML, ESIC-Basaidarapur)

5. 100% DNB

Reservation Policy -

The reservation Policy of the Central Government for the NEET-PGCounselling in All India Quota is as follows –

1. S.C.- 15%

2. S.T.- 7.5%

3. O.B.C.- (Non-Creamy Layer) as per the Central OBC list- 27%

4. EWS- as per Central Government norms- 10%

5. PwD- Horizontal Reservation as per NMC norms- 5%

Candidates who want to avail 5% PwD reservation in PG seats of Govt. /Central medical institutions should obtain a Disability certificate as per 21 Benchmark Disabilities given under RPWD Act 2016 and as per NMC norms, from the designated disability centers as per the list enclosed as Annexure- 2. The certificate issued by any other hospital/ board will not be accepted.

Candidates declared Qualified/Eligible for All India Quota Postgraduate Seats only will be eligible for the online allotment process for All India Quota Seats, which is conducted by the Medical Counseling Committee (MCC), Ministry of Health & Family Welfare, & Government of India. For State Quota, Private medical and dental college seats the candidates are required to contact the appropriate State Government/Admission Authority & Directorate of Medical Education. Medical Counseling Committee (MCC) will not be able to guide candidates in this matter.

Eligibility  -

1. The Candidate should have qualified NEET PG

2. Domicile free

DEEMED UNIVERSITY –

There will be four rounds of Counseling i.e., Round 1 & Round 2, third Round & Stray Vacancy Round, and all the rounds will be conducted by MCC. The Medical Counselling Committee (MCC) of DGHS, MoHFW, shall conduct the counseling for the Stray Vacancy Round of 100% (ALL) seats of Deemed Universities.

All the candidates who have qualified for All India Quota seats on the basis of their rank in NEET PG conducted by NBE including candidates from Union Territory of J&K will be eligible. Eligible candidates may download the Rank letter/ Result from the NBE website.

Reservation Policy –

The eligible Indian National Candidates wanting to get converted to sponsored NRI category will have to submit the following documents as and when the same is called for by the MCC -

1. Documents claiming that the sponsorer is an NRI (Passport, Visa of the sponsorer).

2. Relationship of NRI with the candidate as per the court orders of The Hon’ble Supreme Court of India in case W.P.(c) No. 689/2017- Consortium of Deemed Universities in Karnataka (CODEUNIK) & Ans. Vs Union of India & Ors. Dated 22-08- 2017.

3. Affidavit from the sponsorer that he/ she will sponsor the entire course fee of the candidate duly notarized.

4. Embassy Certificate of the Sponsorer (Certificate from the Consulate).

5. NEET Score Card of the candidate.

6. There will be no reservation for OBC/ SC/ ST/ PWD/EWS candidates in Deemed Universities.

Eligibility Condition -

1. The Candidate should have qualified NEET PG

2. Domicile free

Also Read:MBBS, BDS Admissions in Tamil Nadu: Round 1 NEET Counselling to begin tomorrow, check out details

ARMED FORCES MEDICAL SERVICES (AFMS) –

Candidates who desire to participate in AFMS Counseling will be required to register on the MCC portal i.e., www.mcc.nic.in, and may opt for AFMS seats. The list of registered candidates will be sent to AFMS Authorities for conducting counseling at their own end as per the rules and regulations of AFMS Authorities. The role of MCC is limited to the registration of willing Candidates only. MCC shall not be responsible for any allotment made by or on behalf of the AFMS Authorities.

Candidates must verify the Eligibility Conditions {especially Medical Eligibility/age conditions (up to 35 years of age)} from the AFMS website before applying for AFMS Counselling. There have been instances of cancellation of admission due to non-fulfillment of Medical Eligibility Conditions. (https://www.mod.gov.in/dod/directorate-general- armed-force medical-services).

Candidates must verify their eligibility conditions well before from the AFMS website before applying for AFMS Counselling. MCC will not entertain any grievance regarding the same.

CENTRAL UNIVERSITY/INSTITUTE –

There will be four rounds of counseling i.e., Round 1, Round 2, third Round & Stray Vacancy Round to be conducted by MCC of DGHS. All the candidates who have qualified for All India Quota seats on the basis of their rank in NEET PG conducted by NBE will be eligible for the Fifty percent (50%) AIQ seats of Central University.

The counseling for 50% AIQ is domicile free. The eligibility conditions for the internal quota are given by the colleges/institutes, MCC has no role to play in determining the eligibility conditions for the internal quota of the Central Universities/Institutes.

The candidates are requested to go through the eligibility conditions before applying for the internal quota of the Central Universities/Institutes and ensure that they meet the prescribed eligibility conditions. If any Candidate at any stage of the counseling process is found to have furnished any incorrect/wrong information with regard to his/her eligibility condition, his/her candidature shall be canceled for the further rounds of counseling and the security deposit shall be forfeited.

Reservation of seats under the PWD Category is 5% in Central Universities and the 21 Benchmark Disabilities as envisaged under the regulations of the Rights of Persons with Disabilities Act 2016 and as per NMC norms. For the range of disabilities included, please see Annexure -1 in the notice below. Candidates who want to avail of 5% PwD reservation in PG seats of Govt./Central medical institutions should obtain a Disability certificate as per 21 Benchmark Disabilities given under RPWD Act 2016 and as per NMC norms, from the designated disability centers as per the list enclosed as Annexure- 2 in the notice below. The certificate issued by any other hospital/ board will not be accepted.

DELHI UNIVERSITY (DU) –

Fifty percent (50%) seats will be contributed by Delhi University to All India Quota. For the remaining 50% of seats, candidates who have completed their MBBS from DU are eligible for an Internal Quota of 50% in Delhi University.

Reservation Policy for AIQ seats and Internal seats of DU -

The reservation policy of the Central Government is followed –

1. S.C.- 15%

2. S.T.- 7.5%

3. O.B.C.- (Non-Creamy Layer) as per the Central OBC list- 27%

4. EWS- as per Central Government norms- 10%

5. PwD- Horizontal Reservation as per NMC norms- 5%

6. Reservation of seats under the PWD Category is 5% in AIQ and the twenty one

(21) Benchmark Disabilities as envisaged under the regulations of the Rights of Persons with Disabilities Act 2016 and as per NMC norms. For the range of disabilities included, please see Annexure 1 in the notice below.

Eligibility –

The candidate must have passed the final MBBS examination (for MD/MS/Diploma Course) and BDS examination (for MDS Course) from the University of Delhi and must have completed satisfactorily one-year compulsory rotating internship as of 31st March of the year of admission and must submit their internship completion certificate at the time of admission.

However, for this academic year, the internship completion date may be treated as 11th August 2023 as approved by the competent authority, MoHFW.

ALIGARH MUSLIM UNIVERSITY (AMU) –

Fifty percent (50%) of Seats will be contributed by the AMU to the All India Quota. For the remaining 50% of seats, candidates who have completed their MBBS from AMU are eligible for internal seats of 50% in AMU.

Reservation Policy for AIQ seats -

The reservation policy of the Central Government is followed -

1. S.C.- 15%

2. S.T.- 7.5%

3. O.B.C.- (Non-Creamy Layer) as per the Central OBC list- 27%

4. EWS- as per Central Government norms- 10%

5. PwD- Horizontal Reservation as per NMC norms- 5%

For the Reservation Policy of 50% Internals seats of AMU, there is no reservation.

Eligibility –

An Institutional (Internal) candidate is one who has passed the qualifying examination (MBBS/BDS as applicable) from AMU and completes his/her internship as per the dates specified by AMU authorities.

BANARAS HINDU UNIVERSITY (BHU) –

Fifty percent (50%) of Seats will be contributed by BHU to the All India Quota. For the remaining 50% of seats, candidates who have completed their MBBS/BDS from BHU are eligible for internal seats of 50% in BHU.

Reservation Policy for AIQ and internal seats of BHU -

The reservation policy of the Central Government is followed -

1. S.C.- 15%

2. S.T.- 7.5%

3. O.B.C.- (Non-Creamy Layer) as per the Central OBC list- 27%

4. EWS- as per Central Government norms- 10%

5. PwD- Horizontal Reservation as per NMC norms- 5%.

Eligibility –

Only those Candidates who have passed MBBS/BDS from the Institute of Medical Sciences, BHU as per the internship dates specified by IMS, BHU will be eligible, provided the Candidates have appeared and qualified in NEET-PG Examination.

CENTRAL INSTITUTE OF PSYCHIATRY, RANCHI –

The Institute contributes a hundred percent ( 100%) seats for NEET-PG Counselling. There are no Internal /State quota seats in this Institute/College.

Reservation Policy -

The reservation policy of the Central Government is followed -

1. S.C.- 15%

2. S.T.- 7.5%

3. O.B.C.- (Non-Creamy Layer) as per the Central OBC list- 27%

4. EWS- as per Central Government norms- 10%

5. PwD- Horizontal Reservation as per NMC norms- 5%

LOKOPRIYA GOPINATH BORDOLOI REGIONAL INSTITUTE OF MENTAL HEALTH, TEZPUR –

The Institute contributes 100% of seats for NEET-PG Counselling.

Reservation Policy -

The reservation policy of the Central Government is followed -

1. S.C.- 15%

2. S.T.- 7.5%

3. O.B.C.- (Non-Creamy Layer) as per the Central OBC list- 27%

4. EWS- as per Central Government norms- 10%

5. PwD- Horizontal Reservation as per NMC norms- 5%

CENTRAL INSTITUTES UNDER IP UNIVERSITY- VMMC & SJH, ABVIMS & RML, ESICBASAIDARAPUR –

Fifty percent (50%) seats will be contributed by the Central Institutes (VMMC & SJH, ABVIMS & RML, ESIC-Basaidarapur) to All India Quota. For the remaining 50% seats, candidates who have completed their MBBS/BDS from I.P. University (VMMC & SJH; ABVIMS & RML; Dr. Baba Saheb Ambedkar Medical College & Hospital, New Delhi; Army College of Medical Sciences, Delhi; North Delhi Municipal Corporation (Medical College) Hindu Rao Hospital) are eligible for Internal seats of 50% in Central Institutes (VMMC & SJH, ABVIMS & RML, ESIC-Basaidarapur).

Reservation Policy for AIQ seats and Internal seats of Central Institutes(VMMC & SJH, ABVIMS & RML, ESIC-Basaidarapur):

The reservation policy of the Central Government is followed -

1. S.C.- 15%

2. S.T.- 7.5%

3. O.B.C.- (Non-Creamy Layer) as per the Central OBC list- 27%

4. EWS- as per Central Government norms- 10%

5. PwD- Horizontal Reservation as per NMC norms- 5%

Eligibility –

The Candidates should have completed their MBBS/BDS from I.P. University (VMMC & SJH; ABVIMS & RML; Dr. Baba Saheb Ambedkar Medical College & Hospital, New Delhi; Army College of Medical Sciences, Delhi; North Delhi Municipal Corporation(Medical College) Hindu Rao Hospital) are eligible for Internal seats of 50% in Central Institutes (VMMC & SJH, ABVIMS & RML, ESIC-Basaidarapur).

DIPLOMATE OF NATIONAL BOARD (DNB) –

Medical Counseling Committee conducts counseling for the DNB courses which are domicile free and All India in character in compliance of the Judgment dated 26/05/2020 of the Hon’ble Supreme Court of India in W.P. of 2020 (Diary No. 11011 of 2020) in the matter of Alapati Jyotsana & Ors. v/sUoI & Ors. The Counselling for In-service seats of DNB is not conducted by the MCC of DGHS, MoHFW.

There will be four rounds of counseling i.e. Round 1, Round 2, third Round & Stray Vacancy Round which will be conducted by MCC. All the candidates who have qualified for NEET PG conducted by NBE will be eligible. After the allotment of seats by the MCC of DGHS, the admission fee is collected by NBE Authorities. Hence for any query refer to NBE, MCC has no role in the same, hence MCC will not entertain any requests for a refund.

Reservation Policy -

There will be no reservation in Private DNB Colleges/Institutes.

The reservation policy for the Govt. institutes /Colleges seats contributed by DNB of the Central Government is followed -

1. S.C.- 15%

2. S.T.- 7.5%

3. O.B.C.- (Non-Creamy Layer) as per the Central OBC list- 27%

4. EWS- as per Central Government norms- 10%

5. PwD- Horizontal Reservation as per NMC norms- 5%

Reservation of seats under the PWD Category is 5% in AIQ and the 21 Benchmark Disabilities as envisaged under the regulations of the Rights of Persons with Disabilities Act 2016 and as per NMC norms. For the range of disabilities included, please see Annexure- 1 in the notice below.

Eligibility –

Candidate must have qualified NEET-PG.

Candidates who want to avail of 5% PwD reservation in PG seats of Govt./Central medical institutions should obtain a Disability certificate as per 21 Benchmark Disabilities given under RPWD Act 2016 and as per NMC norms, from the designated disability centers as per the list enclosed as Annexure- 2 in the notice below. The certificate issued by any other hospital/ board will not be accepted.

To view the notice, click on the link below -

https://medicaldialogues.in/pdf_upload/pg-214882.pdf

Also Read:MP DME releases NEET PG Counselling schedule, Registrations from July 25th, Check out complete details

1 year 9 months ago

State News,News,Health news,Delhi,Doctor News,Medical Education,Medical Colleges News,Medical Universities News,Dentistry Education News,Medical Admission News,Latest Medical Education News

Healio News

VIDEO: MOLTO study probes combination therapy in Richter syndrome

In this video, Jakub Svoboda, MD, discusses updated data on the results of the MOLTO study into Richter syndrome presented at ASCO Annual Meeting.Svoboda, an associate professor of medicine at Hospital of the University of Pennsylvaniia, highlighted the study, which examined a combination therapy consisting of venetoclax (Venclexta; Genentech, AbbVie), atezolizumab (Tecentriq, Genentech) and ob

inutuzumab (Gazyva, Genentech) into patients with Richter syndrome, which can be the result of progression from chronic lymphocytic leukemia.“That is a very challenging situation when CLL

1 year 9 months ago

Health News Today on Fox News

Dengue fever cases could reach near-record highs this year: What to know about the tropical infectious disease

The World Health Organization warned on Friday that cases of dengue fever could reach close to record highs this year, partly due to global warming and the way that climate has helped the mosquitoes that spread it, Reuters reported.

The World Health Organization warned on Friday that cases of dengue fever could reach close to record highs this year, partly due to global warming and the way that climate has helped the mosquitoes that spread it, Reuters reported.

Rates of the disease are climbing worldwide, "with reported cases since 2000 up eight-fold to 4.2 million in 2022," according to the same source.

"Europe has reported a surge in cases and Peru declared a state of emergency in most regions."

LISTERIA OUTBREAK KILLS THREE ADULTS IN WASHINGTON STATE, HEALTH DEPARTMENT CONFIRMS

However, international travelers in the U.S. who are looking for protection against this tropical infectious disease spread by mosquitoes will have to wait a little longer. 

On July 11, the Japanese drug-maker Takeda voluntarily withdrew its application to the Food and Drug Administration (FDA) for its dengue vaccine candidate in the U.S. after the agency requested more data that the current trial could not capture, according to a press release. 

A dengue vaccine from the company is already approved in multiple endemic and non-endemic areas, such as the European Union, United Kingdom, Brazil, Argentina, Indonesia and Thailand.

There is only one dengue vaccine approved by the FDA in the U.S., but it is indicated only for children and teenagers ages six to 16 living in endemic areas — mainly Puerto Rico — who have previously had the infection.

The World Health Organization listed dengue fever as one of the top 10 threats to global health in 2019.

Roughly half the world’s population, or about 4 billion people, live in places that are at risk for dengue fever, with some 400 million people infected every year.

One country, Peru, is currently battling its worst outbreak in history.

"Dengue is occurring in urban areas where it did not exist before," Dr. Coralith García, associate professor at the school of medicine at Cayetano Heredia University in Lima, Peru, told Fox News Digital. 

Experts blame warmer temperatures and increased rainfall, but even in Lima, the second largest desert city in the world, dengue is flourishing because "it’s so crowded that anything can happen," she added.

"But Peru had the highest COVID mortality rate [in] the world and now we have several patients dying of dengue, confirming that the Peruvian health system is very weak." 

Most Americans get infected with dengue fever while traveling internationally. 

Yet it can spread locally in several states with hot, humid climates, such as Florida, Hawaii, Texas, and Arizona — although this is not common, according to the Centers for Disease Control and Prevention (CDC).

OHIO WOMAN DETAILS HEALTH JOURNEY AFTER CONTRACTING RARE INFECTIOUS BREAST DISEASE ON A BUSINESS TRIP

From January to June 1 of this year, there were 129 reported cases in the U.S. and 256 reported cases in Puerto Rico, according to the CDC.

Dengue fever is caused by four viruses: dengue virus 1, 2, 3, and 4. 

It is spread primarily by the bite of the Aedes aegypti mosquito, which bites generally during the day, per the CDC.

A person can get infected as many as four times because one virus strain only confers immunity against that specific serotype; people are at higher risk for a life-threatening condition called dengue hemorrhagic fever when they are infected twice, per the CDC.

About one in four people with dengue fever become sick, which can be either a mild or severe illness; but some 40,000 die from severe disease every year, according to the CDC.

Dengue fever is the leading cause of fever among returning travelers to Europe from all continents except Africa, according to a recent study on the tropical disease.

International travelers often complain of a fever with dengue within two weeks after returning home, but symptoms generally resolve within one week.

Dengue has 3 phases of disease: 1) fever phase; 2) critical phase; and 3) recovery phase.

The fever phase, named after its most common symptom, is characterized by severe joint pain and headaches, but most patients recover without complications, Dr. David O. Freedman, professor emeritus of infectious diseases at the University of Alabama at Birmingham, told Fox News Digital.

The disease’s hallmark bone and joint pains have earned it the nickname "breakbone fever."

ARE YOU A MOSQUITO MAGNET? IT MIGHT BE FOR ONE UNPLEASANT REASON 

"In a small proportion of patients, just as the fever is resolving, a second critical phase develops where fluid leaks out of the circulation and gets into body spaces, such as the chest and abdominal cavities," he added. 

During this phase, the blood pressure drops; severe bleeding may also occur.

Freedman recommends watching for abdominal pain or tenderness; 2) persistent vomiting; 3) fluid in body spaces; 4) bleeding from the mouth or rectum; and 5) lethargy and restlessness.

Any of these combined with a fever increase the likelihood of patients becoming very sick and needing to be hospitalized.

He also reminds people that "a total body rash often develops during the critical or early recovery phase."

DANGERS YOU CAN'T SEE MAY BE LURKING IN YOUR UNWASHED BEDDING, SAYS STUDY: BEWARE OF ‘HEALTH CONCERNS’

Freedman noted, "If the patient survives the critical phase usually with medical intervention, the third phase, recovery, occurs about 3-4 days after that."

A recent paper analyzed nearly 6,000 returning travelers with dengue using the GeoSentinel network surveillance platform.

The network is a collaboration between the CDC and the International Society of Travel Medicine. It monitors infectious diseases in 29 countries on six continents that affect international travelers and migrants.

The researchers looked at the patients with dengue fever, which was relatively mild illness without any complications, or "complicated dengue," which included those who had warning signs or severe illness.

They found only 2% of dengue cases were considered "complicated," but approximately 99% had warning signs, with 31% classified as severe.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

"Most of the time it is an uncomplicated course," lead author Ralph Huits, M.D., PhD, department of infectious tropical diseases and microbiology at IRCCS Sacro Cuore Don Calabria Hospital in Negrar, Verona, Italy, told Fox News Digital. 

"You can feel very sick, such as [with] a headache, anorexia, but then get better," he added.

"But some 2% of travelers can have a severe dengue," he continued.

"What you should remember is if you have any of the warning signs, then you or the doctor should monitor them very closely, preferably by hospitalization."

1 year 9 months ago

infectious-disease, Health, lifestyle, insects, climate-change, south-america, Europe, Europe, viruses, headaches-and-migraines

Healio News

The ‘great American switching experiment’: Cyltezo debut ushers in interchangeable era

The hotly debated topic of interchangeability between biologics and biosimilars has officially leapt from the hypothetical realm to clinical practice, ushering in a new era of therapy switching in rheumatology.Cyltezo (adalimumab-adbm, Boehringer Ingelheim), the first biosimilar indicated for certain inflammatory diseases to achieve the interchangeable designation from the FDA, made its U.S.

debut on July 1. This means that it is now possible for a patient being treated with adalimumab (Humira, AbbVie)to be switched to Cyltezo without additional approval from the prescriber.According to the

1 year 9 months ago

Medical News, Health News Latest, Medical News Today - Medical Dialogues |

Cereal bran, especially oat bran useful for controlling BP, cholesterol and blood glucose

Researchers have found in a new study that cereal bran, especially oat bran had a role in controlling BP, cholesterol and blood glucose.

Cardiovascular disease is a prevalent worldwide disease, and cardiometabolic risk factors (CMRFs) include hyperlipidemia, hypertension, diabetes, and adiposity. The researchers  conducted  the study  to investigate the effects of cereal bran consumption on cardiometabolic risk factors.

A study entitled “Effects of cereal bran consumption on cardiometabolic risk factors: A systematic review and meta-analysis” has mentioned that among those with cardiometabolic risk factors or CMRFs, Cereal bran reduces blood pressure, total cholesterol, low-density lipoprotein cholesterol, and fasting blood glucose. Oat bran had the most noticeable effect, they noted.

Cardiovascular disease is highly prevalent. CMRFs include hyperlipidemia, hypertension, diabetes, and adiposity. To control these CMRFs, a healthy diet plays a crucial role in managing CMRFs risks. Cereal bran contains beneficial substances and plays a vital role in this context.

There are still contradictions in the indicators of improving CMRFs by bran from different grain sources or even the same grain source. In this study, researchers investigated the effects of cereal bran consumption on CMRFs using databases like PubMed, Embase, Scopus, the Cochrane Library and Web of Science until February 2023.

The critical points of the study include:

  • The present meta-analysis had 22 studies.
  • Consuming cereal bran has no significant effect on high-density lipoprotein cholesterol, triglycerides, waist circumference, and BMI compared to the control.
  • Cereal bran consumption reduces systolic blood pressure, diastolic blood pressure, total cholesterol, low-density lipoprotein cholesterol and fasting blood glucose with WMD of -1.59, -1.96, -0.19, -0.21 and -0.13, respectively.
  • Oat bran reduced blood lipids in individuals with a history of lipid diseases and blood pressure in patients with a history of obesity and hypertension.

Concluding, Cereal bran reduces blood pressure, total cholesterol, low-density lipoprotein cholesterol, and fasting blood glucose in CMRF individuals, while oat bran had the most obvious effect.

Further reading:

https://www.unboundmedicine.com/medline/citation/37482485/full_citation

1 year 9 months ago

Cardiology-CTVS,Diet and Nutrition,Cardiology & CTVS News,Diet and Nutrition News,Top Medical News

STAT

STAT+: Gene therapy eyedrops restored a boy’s sight. Similar treatments could help millions

MIAMI — Dr. Alfonso Sabater pulled up two photos of Antonio Vento Carvajal’s eyes. One showed cloudy scars covering both eyeballs. The other, taken after months of gene therapy given through eyedrops, revealed no scarring on either eye.

MIAMI — Dr. Alfonso Sabater pulled up two photos of Antonio Vento Carvajal’s eyes. One showed cloudy scars covering both eyeballs. The other, taken after months of gene therapy given through eyedrops, revealed no scarring on either eye.

Antonio, who’s been legally blind for much of his 14 years, can see again.

The teen was born with dystrophic epidermolysis bullosa, a rare genetic condition that causes blisters all over his body and in his eyes. But his skin improved when he joined a clinical trial to test the world’s first topical gene therapy. That gave Sabater an idea: What if it could be adapted for Antonio’s eyes?

Continue to STAT+ to read the full story…

1 year 9 months ago

Biotech, biotechnology

STAT

STAT+: Pharmalittle: Three big drugmakers spent less on lobbying after leaving PhRMA; EMA reviews CRO over data concerns

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online calls, meetings, and deadlines has returned. But what can you do? No matter how hard we try, the world keeps spinning. So time to give it a nudge in a better direction with a cup or three of stimulation.

Our choice today is salted caramel mocha, a touch of the Jersey Shore. Please feel free to join us. Meanwhile, we have assembled a few items of interest for you to peruse as you being your journey. We hope all goes well and that you conquer the world. And of course, do keep in touch. …

The three companies that recently left the Pharmaceutical Research & Manufacturers of America, the industry trade group, all spent less on lobbying following their departures, STAT reports, citing newly released federal disclosures. AbbVie, Teva Pharmaceutical, and AstraZeneca left over a span of five months following the passage of the drug-pricing reform law pushed by Democrats last year. How large members navigate their exits could be instructive to other firms making decisions about their continued membership in the future. Much of PhRMA’s revenue comes from company dues, so exits hurt its bottom line.

Drug companies are systematically funding grassroots patient groups that lobby the U.K. cost-effectiveness watchdog to approve the rollout of their drugs, The Guardian reveals. Of 173 drug appraisals conducted by the National Institute for Health and Care Excellence since April 2021, 138 involved patient groups with a financial link to the maker of the drug being assessed, or have since received funding. Financial interests were often not clearly disclosed in NICE documents. Many of the groups that received payments later made impassioned pleas to NICE for treatments to be approved. Others made submissions appealing NICE decisions when drugs were refused for being too expensive.

Continue to STAT+ to read the full story…

1 year 9 months ago

Pharma, Pharmalot, pharmalittle, STAT+

STAT

STAT+: Lobbying spending dropped for companies that departed PhRMA

WASHINGTON — The three companies that recently left PhRMA all spent less on lobbying following their departures, according to newly released federal disclosures.

PhRMA, the brand-drug industry trade group, lost three members over a span of five months following the passage of Democrats’ drug pricing reform law last year. How large members navigate their exits could be instructive to other firms making decisions about their continued membership in the future. Much of PhRMA’s revenue comes from company dues, so exits hurt the group’s bottom line.

Continue to STAT+ to read the full story…

1 year 9 months ago

Politics, Advocacy, Congress, life sciences, Pharmaceuticals, policy, STAT+, White House

Pages